Cancer vaccines in the coming years are full of optimism, and mRNA cancer vaccines are expected to be available before 2030
Time of Update: 2022-11-01
Breakthroughs in mRNA tumorsAccording to public information, BioNTech is a German biotechnology company, whose main business is to develop and produce effective immunotherapies for the treatment of serious diseases for specific patients.
Trastuzumab subcutaneous preparation approved in China for administration in only 2-5 minutes
Time of Update: 2022-10-12
It is worth mentioning that Roche Pharma China also disclosed that on July 27 this year, the domestic marketing application of Roche pertuzumab trastuzumab injection (subcutaneous injection) was accepted, which is a fixed-dose combination of subcutaneous preparations (trade name Phesgo®), which has previously been approved in the United States, the European Union and other countries and regions for the treatment of early and metastatic HER2-positive breast cancer patients.
Fosun Kite's second CAR-T cell therapy drug FKC889 was approved for clinical use
Time of Update: 2022-05-01
Tecartus® is currently the first and only CAR-T cell therapy approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma5 .
US FDA Approves Kite's Tecartus?, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma.
Potential "first-in-class" new drug approved for clinical use in China
Time of Update: 2022-01-25
TextPharmaceutical GuanlanRecently, the website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China announced that a new class 1 drug named PH94B nasal spray has obtained an implied license for clinical trials and is intended to be developed for: adult social anxiety disorder (SAD) anxiety symptoms .
Corning Jerry KN046 combined with chemotherapy for the treatment of advanced pancreatic cancer phase III registration clinical trial application was approved by CDE
Time of Update: 2022-01-04
HK) announced that the PD-L1/CTLA-4 bispecific antibody KN046 combined with albumin paclitaxel and gemcitabine for the treatment of advanced stages The Phase III registration clinical study (KN046-303) application for pancreatic cancer was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration .
Nobigo® appeared at the 4th CIIE, innovating "Double Ge" to open a new decade of prostate cancer treatment
Time of Update: 2021-11-11
Shanghai, November 6, 2021/PRNewswire/ - On November 6, 2021, the special event "Health Life·Talking about the Prostate Cancer Patient Care Month and Nobigo® Appearance at the CIIE" will be the fourth The Bayer booth at the China International Import Expo was officially launched .
New breakthrough in the field of anti-fibrosis, Ted's overseas authorization sets a record
Time of Update: 2021-03-17
5;">Obtained the national major new drug creation support FDA approval for clinical trials in the United States5;">To this end, in January 2017, Tide Pharmaceuticals formally established the first original innovative drug project-a class 1 small molecule drug TDI01 for the treatment of idiopathic pulmonary fibrosis, which was awarded by the Chinese Academy of Medical Sciences and Peking Union Medical College.
Roche breast cancer drug Patoju monoantigen has been approved for sale
Time of Update: 2021-02-17
Recently, the State Drug Administration approved the import registration application for Pertuzumab Injection, a combination of cocoonumab monoantigen and chemotherapy for complementary treatment of human skin growth factor 2 (HER2) positive early breast cancer patients with a high risk of recurrence.
A large number of medical representatives will be out
Time of Update: 2021-01-07
On the above-mentioned issues, the relevant person responded that the pharmaceutical representative responsible for the treatment of the product can be filled in according to the division of the national list of essential drugs, as for the cooperation of CSO's pharmaceutical representatives, still allow them to carry out academic promotion and other activities, but by the holder of its formal authorization, filing and management.
When will Roche τ anti-inflammatory protein therapy, new alzheimer's disease be overcome
Time of Update: 2020-10-14
for another target of AD drugs β amyloid protein (A beta), AC Immune, in collaboration with Genentek, conducted a five-year prevention trial against A-beta monoantigen crenezumab, which is expected to be available in 2022.
AJOG: CD70 Antibody-Drug Coupler is expected to be a target drug for uterine smooth muscoma
Time of Update: 2020-09-23
researchers first screened target membrane proteins by comparing the expression of membrane proteins in three uterine smooth muscular tumor cell lines (SK-UT-1, SK-LMS-1 and SKN) and normal uterine myoblasts.
Extending the Life of AML Patients for the First Time FDA approves the first ongoing treatment
Time of Update: 2020-09-19
Onureg is the first and only AML continuous treatment drug approved by the FDA for patients with remission, an oral low methylation preparation.
" References: U.S. Food and Drug Administration Approves Onureg® (azacitidine tablets), a New Oral Therapy, as Continued Treatment for Adults in First Remision With Acute Myeloid Leukemia.
Wuhu, Anhui Province: A batch of cheap shortage of drugs has gone up in price (with list
Time of Update: 2020-09-19
Medicine Network September 11th, September 9th, Wuhu City, Anhui Province, pharmaceutical medical supplies management center issued the "2020 municipal public hospital drug price adjustment public not
The most popular stomach-powered drug Fujian Haixi was the first to be evaluated
Time of Update: 2020-07-20
Pharmaceutical Network June 23rd, Fujian Haixi new drug creation according to the imitation of 4 categories of declaration of the oxalic acid Moshabili tablets approved production, as through consistency evaluation, as the first in the country According to Minet.com, sales of Moshabili tablets at the end of China's public medical institutions in 2019 were 704 million yuan, ranking first in the competitive landscape of gastric-powered drug products .
Panobinostat - A new chemotherapy drug for children's DIPG
Time of Update: 2020-06-29
Ref: Grasso CS, e t al . Nat Med 2015 Jul; 21(7): 827. doi: 10. 1038/nm0715-827a.) diffuse brain bridge glioma (DIPG) is a common brain stem malignant tumor in children, the average survival time of